Olutasidenib Market Introduction: Olutasidenib is emerging as a pivotal drug in the oncology field, targeting cancers with specific genetic mutations. Developed to inhibit the mutant form of the isocitrate dehydrogenase 1 (IDH1) enzyme, olutasidenib offers a targeted approach for treating cancers driven by IDH1 mutations, particularly acute myeloid leukemia (AML). Unlock your...